• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

    4/25/25 8:00:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • First-to-market innovations enhance efficiency, including HYPERVIT 30K, the world's fastest vitrectomy probe executing 30,000 cuts per minute1-3
    • Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye, supporting excellent patient care4,*,†
    • Inventory will begin shipping to Australia, Europe, Japan and the U.S. from May onwards

    Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to deliver superior efficiency for vitreoretinal and cataract surgery, while enabling exceptional outcomes for patients.2,4-6,* The systems feature many first-to-market technologies designed to deliver transformative surgical innovation for cataract and vitreoretinal surgery, including UNITY 4D Phaco, HYPERVIT® 30K and the advanced UNITY Intelligent Fluidics system.1,4-7 With UNITY VCS/CS, surgeons can operate at more physiologic conditions without compromising efficiency.1 Surgeons will have the opportunity for hands on experience with UNITY VCS/CS during the 2025 American Society for Cataract and Refractive Surgeons annual meeting (ASCRS, Los Angeles, April 25-28) at the Alcon Booth (#1815).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423876252/en/

    UNITY® VCS/CS Logo

    UNITY® VCS/CS Logo

    "Alcon has a long legacy of advancing phaco and vitreoretinal technology for surgical ophthalmology. With UNITY VCS/CS, we are introducing more than a dozen innovations designed to transform surgical outcomes while delivering significant efficiencies for surgery centers across the globe," said David Endicott, CEO of Alcon. "This tremendous accomplishment could not have been achieved without those who participated in the development process, including the surgeons who have been evaluating the machines in their practices over the last year. We are excited to start shipping inventory next month so more practices can experience this extraordinary innovation."

    The combination vitreoretinal and cataract system intelligently transforms vitreoretinal and cataract surgery with significant innovation. With the introduction of UNITY Intelligent Fluidics, a unique pressure and flow control technology with real-time sensing, surgeons can expect surgical stability and efficiency at each step of the procedure.1 Significant advancements in instrumentation for vitreoretinal surgery include:

    • UNITY 27 Gauge Portfolio: Instrumentation that through breakthrough design and the inclusion of the Dynamic Stiffener technology, surpasses the limitations of traditional 27-gauge tools, delivering the stiffness of a 25-gauge system or better, in a smaller gauge.6
    • UNITY TetraSpot: A multi-spot illuminated laser probe that reduces laser application time by up to three times, enabling surgeons to deliver one, two, or four simultaneous laser spots for greater procedural versatility.5,‡
    • UNITY Illumination: Reduces blue light exposure to the eye and includes customizable light profiles for excellent tissue visualization, while providing up to 10,000 hours of reliability.1,8

    "UNITY VCS has truly revolutionized the way I can perform during vitreoretinal surgeries," said Maria H. Berrocal, MD, CEO, Drs. Berrocal & Associates. "During my approximately 130 cases with this new technology, I saw efficiencies across surgery types. The unique fluidics control together with the faster cutting speeds have certainly been a game-changer, as well as the 27 gauge portfolio—taking the instrumentation to the next level with stiffness and performance similar to 25 gauge—all delivering stability and efficiency throughout the procedure."

    The UNITY VCS/CS system is designed to allow cataract surgeons to operate with increased stability and efficiency at more physiologic conditions through its Intelligent Fluidics functionality.1 This new technology maintains a consistent level of intraocular pressure (IOP)∞ to help support patient comfort during surgery, while allowing for higher average vacuum during lens removal.1 Other surgical performance enhancements include:

    • UNITY Intelligent Sentry: Maintains anterior chamber stability while improving upon CENTURION® Vision System with ACTIVE SENTRY®, reducing post-occlusion surge volumes by 44%.9,*
    • UNITY Thermal Sentry: The first phacoemulsification handpiece that features a thermal sensor that works with a proprietary algorithm to estimate incision temperature in real-time and regulate ultrasound power.1

    "I perform thousands of cataract surgeries each year and UNITY VCS/CS has streamlined my surgical procedures while enabling us to consistently deliver exceptional patient outcomes," said John Berdahl, MD. "The UNITY 4D phaco technology in particular has been impressive—breaking up even large, dense cataracts efficiently, while maintaining more physiologic IOP throughout the surgery. Beyond the device performance, it expedites our surgical workflow and introduces significant usability improvements—which the entire team greatly appreciates."

    UNITY VCS/CS is the first product to become available from Alcon's UNITY portfolio of next-generation surgical equipment solutions. UNITY VCS/CS users can benefit from Intelligent Services Solutions, including select remote service offerings and predictive service capabilities to minimize downtime. UNITY VCS has received CE Mark, and regulatory approvals in Australia, Japan and the U.S. Inventory will begin shipping to Australia, Europe, Japan and the U.S. from May onwards; and to other markets in third quarter of 2025 pending regulatory approvals. Surgeons attending the ASCRS annual meeting can demo the UNITY VCS/CS platform at Alcon Booth #1815. For more information, please visit MyAlcon.com or speak to your Alcon Sales Representative.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    About UNITY® VCS/CS

    Indications / Intended Use: The UNITY® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) and posterior segment (i.e. vitreoretinal) ophthalmic surgery. In addition, with the optional laser this system is indicated for photocoagulation (i.e. vitreoretinal and macular pathologies), iridotomy and trabeculoplasty procedures. The UNITY® CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e. phacoemulsification and removal of cataracts) ophthalmic surgery. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.

    *Based on bench data; reduction in surge is correlated to less change in anterior chamber depth.

    †Based on N=10 handpieces, Artificial cataract lens IOP 55mmhg vacuum of 450 mmHg.

    ‡Multiple-spot laser probe (4) is 3 times faster than single-spot laser probe.

    ∞Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively.

    References

    1. UNITY™ VCS and CS User Manual.
    2. Alcon Data on File, 2024. [REF-24644]
    3. Irannejad A, Tambat S, Abulon DJK. Retropulsion and Mass flow of 27-gauge Vitrectomy Probes: Comparison of Dual-blade/flat-tipped probes and single-blade/beveled probes. 2021. Poster presentation.
    4. Alcon Data on File, 2024. [REF-24379]
    5. Alcon Data on File, 2024. [REF-24615]
    6. Alcon Data on File, 2024. [REF-24576]
    7. Unity Phaco Handpiece Directions for Use.
    8. Alcon Data on File, 2024. [REF-24760]
    9. Alcon Data on File, 2024. [REF-25562]

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250423876252/en/

    Investor Relations

    Daniel Cravens, Allen Trang

    + 41 589 112 110 (Geneva)

    + 1 817 615 2789 (Fort Worth)

    [email protected]

    Media Relations

    Steven Smith

    + 41 589 112 111 (Geneva)

    + 1 817 551 8057 (Fort Worth)

    [email protected]

    Get the next $ALC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    3/25/2025Neutral → Buy
    BofA Securities
    1/24/2025$108.00 → $106.00Buy
    Needham
    1/10/2025Neutral → Buy
    Redburn Atlantic
    12/17/2024$103.00 → $108.00Buy
    Needham
    11/12/2024Buy
    Needham
    10/10/2024Sell → Neutral
    Redburn Atlantic
    More analyst ratings

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

      First-to-market innovations enhance efficiency, including HYPERVIT 30K, the world's fastest vitrectomy probe executing 30,000 cuts per minute1-3 Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye, supporting excellent patient care4,*,† Inventory will begin shipping to Australia, Europe, Japan and the U.S. from May onwards Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS).

      4/25/25 8:00:00 AM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    SEC Filings

    See more
    • SEC Form 6-K filed by Alcon Inc.

      6-K - ALCON INC (0001167379) (Filer)

      5/13/25 4:31:01 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form 6-K filed by Alcon Inc.

      6-K - ALCON INC (0001167379) (Filer)

      4/4/25 8:36:59 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form 20-F filed by Alcon Inc.

      20-F - ALCON INC (0001167379) (Filer)

      2/25/25 4:34:11 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alcon Inc.

      SC 13G - ALCON INC (0001167379) (Subject)

      2/13/24 3:47:46 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

      SC 13G/A - ALCON INC (0001167379) (Subject)

      2/10/23 1:35:38 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

      SC 13G/A - ALCON INC (0001167379) (Subject)

      2/10/22 5:01:03 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Financials

    Live finance-specific insights

    See more
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Publishes Agenda for 2025 Annual General Meeting

      Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f

      4/4/25 1:00:00 AM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Alcon with a new price target

      BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

      5/14/25 11:06:26 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Needham reiterated coverage on Alcon with a new price target

      Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously

      3/28/25 7:39:07 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon upgraded by BofA Securities

      BofA Securities upgraded Alcon from Neutral to Buy

      3/25/25 8:19:22 AM ET
      $ALC
      Ophthalmic Goods
      Health Care